Algorithme Pharma announce Dr. Robert Massé as Vice President – Large Molecule Bioanalysis.

Algorithme Pharma announces another key strategic appointment. Laval, Monday, March 7, 2011 – Chris Perkin, President and Chief Executive Officer, is pleased to announce the appointment of Dr. Robert Massé as Vice President – Large Molecule Bioanalysis.

Algorithme Pharma announces another key strategic appointment.

Laval, Monday, March 7, 2011 – Chris Perkin, President and Chief Executive Officer, is pleased to announce the appointment of Dr. Robert Massé as Vice President – Large Molecule Bioanalysis. 

This key appointment reinforces Algorithme Pharma’s commitment to growth and customer service. It also reflects the company’s goal to remain an industry leader in the Life Science contract research market.

In this newly created position, Dr. Massé will define and implement Algorithme Pharma's new Large Molecule Bioanalysis strategy to achieve the best fit with our clients’ needs and expectations. He will be based in our Laval (Quebec-Canada) office and will be responsible for the development of an integrated approach to the large molecule business in addition to working closely with the Company's small molecule bioanalysis services and identifying new opportunities within this market.

Dr. Massé is a seasoned executive with extensive experience in leading bioanalysis laboratories in Contract Research Organizations. Prior to joining Algorithme Pharma, Dr. Robert Massé held senior positions at LAB Pharmacological Research, Phoenix International Life Sciences, MDS Pharma Services and more recently Anapharm where he was Vice President Bioanalysis and based in Quebec City (Canada).

Dr. Massé holds a Ph.D. Bioorganic Chemistry Degree from the University of Montreal and an industrial Post-doctoral Fellowship from Bristol-Myers Squibb and NSERC. 

About Algorithme Pharma
As a major global player in Clinical Research and Bioanalysis, Algorithme Pharma provides a wide range of services for bioequivalence and early stage development (Phase I/IIa) studies to the pharmaceutical, and biotechnology industries. In addition to its multi-unit clinical facilities in Canada and the United Kingdom, Algorithme Pharma offers different services including protocol designs, CTD/ICH clinical reports, data management, biostatistics, quality assurance and regulatory affairs. Successfully audited by the US FDA, Canada TPD, Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES regulatory authorities, Algorithme Pharma conducts over 275 clinical trials per year.